The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up

PurposeThe Intergroup 0116 trial has demonstrated that postoperative chemoradiotherapy (CRT) improves survival in gastric cancer. We retrospectively compared survival and recurrence patterns in two phase I/II studies evaluating more intensified postoperative CRT with those from the Dutch Gastric Cancer Group Trial (DGCT) that randomly assigned patients between D1 and D2 lymphadenectomy.Patients and MethodsSurvival and recurrence patterns of 91 patients with adenocarcinoma of the stomach who had received surgery followed by radiotherapy combined with fluorouracil and leucovorin (n = 5), capecitabine (n = 39), or capecitabine and cisplatin (n = 47) were analyzed and compared with survival and recurrence patterns of 694 patients from the DGCT (D1, n = 369; D2, n = 325). For both groups, the Maruyama Index of Unresected Disease (MI) was calculated and correlated with survival and recurrence patterns.ResultsWith a median follow-up of 19 months in the CRT group, local recurrence rate after 2 years was significantly higher in the surgery only (DGCT) group (17% v 5%; P = .0015). Separate analysis of CRT patients who underwent a D1 dissection (n = 39) versus DGCT-D1 (n = 369) showed fewer local recurrences after chemoradiotherapy (2% v 8%; P = .001), whereas comparison of CRT-D2 (n = 25) versus DGCT-D2 (n = 325) demonstrated no significant difference. CRT significantly improved survival after a microscopically irradical (R1) resection. The MI was found to be a strong independent predictor of survival.ConclusionAfter D1 surgery, the addition of postoperative CRT had a major impact on local recurrence in resectable gastric cancer.

Download Full-text

Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer

The American Journal of Surgery ◽

10.1016/s0002-9610(00)00549-3 ◽

2001 ◽

Vol 181 (1) ◽

pp. 16-19 ◽

Cited By ~ 90

Author(s):

Daniele Marrelli ◽

Enrico Pinto ◽

Alfonso De Stefano ◽

Maurizio Farnetani ◽

Lorenzo Garosi ◽

...

Keyword(s):

Gastric Cancer ◽

Clinical Utility ◽

Resectable Gastric Cancer

Download Full-text

New European guidelines for the management of patients with precancerous changes in the stomach

Medical Council ◽

10.21518/2079-701x-2019-3-44-47 ◽

2019 ◽

pp. 44-47

Author(s):

V. V. Tsukanov ◽

A. V. Vasyutin ◽

J. L. Tonkih ◽

O. V. Peretyatko

Keyword(s):

Gastric Cancer ◽

Helicobacter Pylori ◽

Clinical Practice ◽

Stomach Cancer ◽

Adequate Treatment ◽

European Guidelines ◽

Important Principle ◽

Tumor Pathology ◽

Gastric Cancer Prevention

Aim of the review: to analyze the current aspects of the management of patients with precancerous changes in the stomach, as outlined in the new MAPS II European recommendations.Basic provisions. For qualified diagnosis of precancerous changes in the stomach it is necessary to use modern endoscopic and morphological methods. Timely detection of atrophy, metaplasia and dysplasia significantly increases the effectiveness of gastric cancer prevention. Eradication of Helicobacter pylori infection is an important principle in the management of patients with precancerous changes in the stomach.Conclusion. According to European recommendations, timely diagnosis, adequate treatment and follow-up of patients with precancerous gastric changes play an important role in the prevention of stomach cancer. The application of such principles in daily clinical practice will allow standardization of the approach to the management of patients with pre-tumor pathology.

Download Full-text

Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial

Journal of Clinical Oncology ◽

10.1200/jco.2005.05.189 ◽

2005 ◽

Vol 23 (23) ◽

pp. 5404-5405 ◽

Cited By ~ 9

Author(s):

Roderich E. Schwarz ◽

David D. Smith

Keyword(s):

Gastric Cancer ◽

Lymph Node ◽

Lymph Node Dissection ◽

Node Dissection ◽

Extended Lymph Node Dissection ◽

Cancer Group ◽

Group Trial ◽

Benefit Final ◽

Gastric Cancer Group

Download Full-text

Prognostic Significance of Cytosolic pS2 Protein Content in Gastric Cancer

The International Journal of Biological Markers ◽

10.1177/172460080101600105 ◽

2001 ◽

Vol 16 (1) ◽

pp. 37-44 ◽

Cited By ~ 9

Author(s):

C. Suárez ◽

F. Vizoso ◽

J.C. Rodríguez ◽

I. García ◽

P. Raigoso ◽

...

Keyword(s):

Gastric Cancer ◽

Standard Error ◽

Prognostic Significance ◽

Biological Marker ◽

Tumor Location ◽

Adjacent Mucosa ◽

Gastric Adenocarcinomas ◽

Resectable Gastric Cancer ◽

Clinicopathologic Parameters

pS2, a 60-amino-acid chain peptide which is the most widespread estrogen-induced RNA messenger in MCF-7 breast cancer cells, is normally detected in the epithelium of gastric mucosa. The aims of this work were to evaluate the cytosolic pS2 content and its clinical significance in gastric carcinomas. Cytosolic pS2 levels were examined by immunoradiometric methods in 108 patients with primary gastric adenocarcinomas. The mean follow-up period was 23.3 months. The cytosolic pS2 levels of the tumors ranged widely, i.e., from 0.1 to 3217 ng/mg protein. There were no significant differences in pS2 content between tumors (mean ± standard error: 137.2±31.4 ng/mg protein) and paired adjacent mucosa samples (n=84; mean ± standard error: 249.6±32.6 ng/mg protein), nor were there any significant differences in tumoral pS2 levels with respect to clinicopathologic parameters such as patient age and sex or tumor location, stage, histologic type or grade. However, the results indicated that high intratumoral pS2 levels were significantly and independently associated with an unfavorable outcome in the overall group of patients (p=0.0266) and in patients with resectable gastric cancer (p=0.003). In conclusion, pS2 may represent a useful biological marker in gastric cancer.

Download Full-text